利福平耐药结核病临床结局的药代动力学-药效学决定因素:多中心前瞻性队列研究
在坦桑尼亚、孟加拉国和俄罗斯联邦纳入290例成人肺结核利福平耐药/耐多药结核病患者,检测血清药物AUC0-24与MIC并评估AUC0-24/MIC靶值与治疗结局的关联;莫西沙星靶值58与良好结局相关,左氧氟沙星118.3、氯法齐明50.5及吡嗪酰胺AUC0-24 379 mg×h/L与更快培养转阴相关。
要点
- 莫西沙星AUC0-24/MIC靶值58与良好治疗结局相关(OR 3.75,95%CI 1.21-11.56,P=.022)。
- 左氧氟沙星AUC0-24/MIC 118.3、氯法齐明50.5及吡嗪酰胺AUC0-24 379 mg×h/L与更快培养转阴相关(HR>1.0,P<.05)。
- 按AUC0-24/MIC聚类显示多药暴露最低者培养转阴最慢。
核心结论
- 在利福平耐药/耐多药结核多药方案中,血清药代动力学与结核分枝杆菌MIC存在变异,氟喹诺酮类、吡嗪酰胺和氯法齐明的特定参数具有预测性,应优化以改善临床结局。
研究设计与样本
- 多中心前瞻性队列研究,纳入坦桑尼亚、孟加拉国和俄罗斯联邦接受当地方案的成人肺结核利福平耐药/耐多药结核病患者,2016年6月至2018年7月入组。
主要发现
- 290例患者中62例(21%)治疗失败,包括30例死亡。
- 莫西沙星AUC0-24/MIC靶值58与良好治疗结局相关(OR 3.75,95%CI 1.21-11.56,P=.022)。
- 左氧氟沙星AUC0-24/MIC 118.3、氯法齐明AUC0-24/MIC 50.5和吡嗪酰胺AUC0-24 379 mg×h/L与更快培养转阴相关(HR>1.0,P<.05)。
- 其他单药暴露无预测作用。
- 按AUC0-24/MIC聚类显示多药暴露最低者培养转阴最慢。
关键数值与推荐
- 莫西沙星AUC0-24/MIC靶值58与良好治疗结局的OR为3.75(95%CI 1.21-11.56,P=.022)。
- 左氧氟沙星AUC0-24/MIC 118.3、氯法齐明AUC0-24/MIC 50.5和吡嗪酰胺AUC0-24 379 mg×h/L与更快培养转阴相关(HR>1.0,P<.05)。
临床怎么用
- 作者认为氟喹诺酮类、吡嗪酰胺和氯法齐明的特定药代动力学-药效学参数具有预测性,应优化以改善临床结局。
- 原文未据此给出具体用药推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rifampin-resistant and/or multidrug-resistant tuberculosis (RR/MDR-TB) treatment requires multiple drugs, and outcomes remain suboptimal. Some drugs are associated with improved outcome. It is unknown whether particular pharmacokinetic-pharmacodynamic relationships predict outcome. METHODS: Adults with pulmonary RR/MDR-TB in Tanzania, Bangladesh, and the Russian Federation receiving local regimens were enrolled from June 2016 to July 2018. Serum was collected after 2, 4, and 8 weeks for each drug's area under the concentration-time curve over 24 hours (AUC0-24). Quantitative susceptibility of the M. tuberculosis isolate was measured by minimum inhibitory concentrations (MICs). Individual drug AUC0-24/MIC targets were assessed by adjusted odds ratios (ORs) for favorable treatment outcome, and hazard ratios (HRs) for time to sputum culture conversion. K-means clustering algorithm separated the cohort of the most common multidrug regimen into 4 clusters by AUC0-24/MIC exposures. RESULTS: Among 290 patients, 62 (21%) experienced treatment failure, including 30 deaths. Moxifloxacin AUC0-24/MIC target of 58 was associated with favorable treatment outcome (OR, 3.75; 95% confidence interval, 1.21-11.56; P = .022); levofloxacin AUC0-24/MIC of 118.3, clofazimine AUC0-24/MIC of 50.5, and pyrazinamide AUC0-24 of 379 mg × h/L were associated with faster culture conversion (HR >1.0, P < .05). Other individual drug exposures were not predictive. Clustering by AUC0-24/MIC revealed that those with the lowest multidrug exposures had the slowest culture conversion. CONCLUSIONS: Amidst multidrug regimens for RR/MDR-TB, serum pharmacokinetics and M. tuberculosis MICs were variable, yet defined parameters to certain drugs-fluoroquinolones, pyrazinamide, clofazimine-were predictive and should be optimized to improve clinical outcome. CLINICAL TRIALS REGISTRATION: NCT03559582.
引用
- Heysell SK, Mpagama SG, Ogarkov OB, et al. Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study. Clin Infect Dis. 2023. PMID: 35731948. doi:10.1093/cid/ciac511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。